Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Assets: 2020-2025

Historic Assets for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $371.0 million.

  • Arcutis Biotherapeutics' Assets fell 15.18% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.0 million, marking a year-over-year decrease of 15.18%. This contributed to the annual value of $348.9 million for FY2024, which is 2.20% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Assets is $371.0 million, which was up 5.26% from $352.4 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Assets' 5-year high stood at $508.9 million during Q3 2022, with a 5-year trough of $293.0 million in Q3 2023.
  • Moreover, its 3-year median value for Assets was $352.4 million (2025), whereas its average is $373.8 million.
  • In the last 5 years, Arcutis Biotherapeutics' Assets skyrocketed by 95.45% in 2021 and then crashed by 42.43% in 2023.
  • Arcutis Biotherapeutics' Assets (Quarterly) stood at $408.2 million in 2021, then climbed by 10.08% to $449.3 million in 2022, then declined by 24.02% to $341.4 million in 2023, then climbed by 2.20% to $348.9 million in 2024, then dropped by 15.18% to $371.0 million in 2025.
  • Its Assets stands at $371.0 million for Q3 2025, versus $352.4 million for Q2 2025 and $344.1 million for Q1 2025.